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DEFIC IENT INTERLEUKIN  2 ACT IV ITY  IN MRL/Mp AND 
C57BL/6 J  M ICE  BEARING THE lpr GENE* 
By DAVID WOFSY, EDWIN D. MURPHY, JOHN B. ROTHS, MICHAEL J. 
DAUPHINI~E, STUART B. KIPPER, AND NORMAN TALAL:]: 
From the Section of Immunology~Arthritis, Veterans Administration Medical Center, San Francisco, 
California 94121; the Department of Medicine, University of California, San Francisco, California 94121; 
and The Jackson Laboratory, Bar Harbor, Maine 04069 
MRL/Mp-lpr/ lpr (MRL-lpr) mice spontaneously develop autoimmune disease char- 
acterized by antibodies to nucleic acids, immune complex glomerulonephritis, and 
death from renal failure (1, 2). They have certain unique features that make them 
particularly interesting murine models for systemic lupus erythematosus (SLE).I First, 
they develop massive generalized lymphadenopathy associated with proliferation of 
Lyt-1+23 - T cells (3). Second, they exhibit excessive T helper function (4, 5). Finally, 
a single autosomal recessive gene, lpr, is responsible for both the ly.mphoproliferation 
and severe autoimmunity of MRL-lpr mice (1). 
Several immunoregulatory abnormalities that might contribute to autoimmunity 
in MRL-lpr mice have been identified (1-11). These include defective feedback 
suppression i  vitro (6), as well as T helper lymphoproliferation in vivo (3, 4). Studies 
in two laboratories (10, 11) have focused attention on the syngeneic mixed lymphocyte 
reaction (SMLR), which is decreased before the onset of clinical illness. Failure to 
develop an SMLR is an early and consistent feature in murine models of SLE and 
may represent a common predisposition to autoimmunity (10, 11). 
To clarify the molecular basis for abnormal immunoregulation i  MRL-lpr mice, 
we examined their ability to produce and respond to interleukin 2 (IL-2). IL-2, 
previously called T cell growth factor, is a lymphokine produced by mitogen- or 
antigen-stimulated T cells (12). It is also produced during the course of a normal 
SMLR (13). IL-2 has significant T cell regulatory function (14-18). It stimulates 
thymocyte proliferation (14, 15), provides helper activity for antibody production 
(14-16), facilitates the induction of cytotoxic T cells (14-18), and promotes the 
proliferation of helper and cytotoxic T lymphocytes in long-term culture (15, 19, 20). 
We found that MRL-lpr mice have a progressive defect in the ability to produce IL- 
2. Furthermore, spleen cells from MRL-lpr mice fail to respond normally to IL-2. IL- 
2 deficiency precedes the onset of clinical illness and becomes increasingly severe with 
age. 
* Supported by the Veteran's Administration; grant AI-15550-A from the National Institutes of Health; 
grant GA-77-101 from the State of California; and by the Northern California chapter of the Arthritis 
Foundation. 
:l: To whom correspondence should be addressed at the Veterans Administration Medical Center and 
University of Texas Health Science Center, San Antonio, Tex. 78229. 
1 Abbreviations used in this paper: Con A, concanavalin A; IL-1, IL-2, interleukin 1and 2; PMA, phorbol 
myristic acetate; SLE, systemic lupus erythematosus; SMLR, syngeneic mixed lymphocyte r action. 
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We have transferred the lpr gene from the MRL-lpr mice onto the C57BL/6J  
background by eight cycles of cross-intercross mating. We found that, like MRL-lpr 
mice, C57BL/6J-lpr/lpr (B6-1pr) mice develop an autoimmune disease characterized 
by lymphadenopathy, antinuclear antibodies, and early mortality. Moreover, they 
lose the ability to produce and respond to IL-2. In contrast, control C57BL/6 J -+/+ 
(B6-+/+) mice lacking the lpr gene have normal IL-2 production and response. These 
findings suggest hat homozygosity at the lpr locus results in both autoimmunity and 
deficiency of IL-2 activity. Our  results further suggest that IL-2 deficiency may 
contribute to the immunoregulatory abnormalities that underlie murine lupus. 
Mater ia ls  and  Methods  
Mice. MRL-lpr, MRL/Mp-+/+ (MRL-+/+), and B6-lpr breeding pairs were obtained 
from The Jackson Laboratory, Bar Harbor, Maine, and were maintained at the University of 
California, San Francisco Vivarium, and the Veterans Administration Medical Center, San 
Francisco. MRL-lpr and MRL-+/+ are congenic strains with 99.6% genetic homology. MRL- 
+/+ mice lack the autosomal recessive gene responsible for accelerated autoimmunity and 
lymphoproliferation in MRL-lpr mice (1). 
Culture Medium. RPMI 1640 medium (Cell Culture Facility, University of California, San 
Francisco, Calif.) was supplemented with 10% heat-inactivated fetal calf serum (Sterile Systems, 
Inc., Logan, Utah), 1 mM glutamine, 0.1 mM nonessential mino acids, 1 pM sodium pyruvate, 
100 U/ml penicillin, 100 #g/ml streptomycin, 50 #g/ml gentamycin, and 5 × 10 -s M 2- 
mercaptoethanol. This medium was used in the production and testing of IL-2. 
IL-2 Production. Spleen cells were suspended at a density of 1 × 10/ml in culture medium 
supplemented with 10/~g/ml concanavalin A (Con A; Miles Laboratories, Inc., Elkhart, Ind.). 
The cells were incubated in Falcon 3008 multiwell tissue culture plates (Falcon Labware, 
Oxnard, Calif.) for 36 h at 37°C in a humidified atmosphere containing 5% CO2. These 
conditions are optimal for production of IL-2 by murine spleen cells (21). Cells were removed 
from the culture supernatants by centrifugation at 1,500 g for 10 min. Cell-free supernatants 
were subsequently passed through 0.22-/~m filters (Millipore Corp., Bedford, Mass.) and stored 
at -20°C. 
IL-2 Assay. IL-2 activity was measured using a slight modification of the technique of 
Smith et al. (22). Normal spleen cells were cultured for 48 h with Con A (2 /~g/ml) and 
subsequently washed three times in 10 mg/ml a-methyl-v-mannoside (Sigma Chemical Co., St. 
Louis, Mo.). The cells were then incubated in 96-well microtiter plates (Linbro Scientific, Inc., 
Hamden, Conn.) with serial dilutions of the culture supernatant being tested for IL-2 activity. 
Each well contained 5 × 103 cells in a volume of 200/tl. Cultures were supplemented with 10 
mg/ml a-metbyl-D-mannoside to block the possible mitogenic effects of Con A in the test 
samples. They were maintained at 37°C in a humidified atmosphere of 5% CO2. 1 /~Ci of 
[3H]thymidine added during the last 24 h of a 72-h incubation yielded optimal thymidine 
incorporation. The cultures were then harvested onto glass fiber filter strips, and retained 
radioactivity was measured in a Packard liquid scintillation counter (Packard Instrument Co., 
Downers Grove, Ill.). 
In preliminary experiments, it was determined that spleen cells from MRL-+/+, B6-+/+, 
and DBA/2 mice proliferated comparably in response to IL-2. Therefore, we used MRL-+/+ 
spleen cells in our assay of IL-2 activity. 
IL-2 Response. The assay described above was also used to determine the ability of MRL-lpr 
spleen cells to respond to IL-2. This was accomplished by incubating Con A-activated MRL-lpr 
spleen cells with supernatants known to contain IL-2. The preparation of partially purified 
human IL-2 (Associated Biomedie Systems, Inc., Buffalo, N. Y.) used in these experiments has 
been described previously (23). 
IL-2 Absorption. Fresh spleen cells from MRL-lpr and MRL-+/+ mice were stimulated with 
Con A (2 #g/ml) for 48 h, washed three times in a-methyl-n-mannoside (10mg/ml), and 
incubated with a standard IL-2 preparation (5 × 107 cells/ml) for 2 h at 37°C. After incubation, 
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the cells were removed by centrifugation at 1,500 g for 10 min, and the remaining supernatants 
were tested for IL-2 activity. 
Interleukb2 1 (IL-1) Production. The IL-1 used in these experiments was generously provided 
by Dr. Robert Mishell of the University of California at Berkeley. Briefly, macrophage culture 
supernatants were derived from PU5-1.8 cells as described previously (24) and tested for IL-1 
activity in the thymocyte proliferation assay of Farrar et al. (25). Culture supernatants retained 
50% maximum activity in the IL-1 assay at a 1:32 dilution. 
Results 
IL-2 Production by MRL-lpr Spleen Cells. MRL-lpr mice had a marked defect in IL- 
2 production that was already prominent early in life and increased with age (Fig. 1). 
Culture supernatants derived from 2-mo-old MRL-lpr mice had relatively little IL-2 
activity even at the highest concentration tested (1:2), and had no activity beyond a 
1:4 dilution. In contrast, culture supernatants derived from age-matched MRL-+/+ 
mice retained activity through a 1:64 dilution (Fig. 1 a). By 5 mo of age, the defect in 
IL-2 production was virtually absolute (Fig. 1 b). The reduction in IL-2 activity was 
independent of the duration of culture or the dose of Con A used (Fig. 2). 
Effect of MRL-lpr Spleen Cells on IL-2 Production by MRL-+ / + Spleen Cells. To 
determine whether suppressor cells were responsible for IL-2 deficiency in MRL-lpr 
mice, we co-cultured equal concentrations (5 × 106 cells/ml) of lymphocytes from 5- 
mo-old MRL-+/+ and MRL-lpr mice. Control cultures consisted of either MRL-+/  
+ or MRL-lpr cells alone. In four separate xperiments, we found no evidence of 
cellular suppression of IL-2 production. A representative experiment is shown in Fig. 
3. These results also imply that MRL-lpr spleen cells do not produce a soluble 
inhibitor of IL-2 activity. I f  such an inhibitor were produced, it would have inhibited 
IL-2 activity in the mixed cell cultures as well as in the cultures containing MRL-lpr 
cells only. 
Effect of Macrophage-replacing Factors on IL-2 Production. IL-2 production is macro- 
phage dependent (26). Farrar et al. have shown that the requirement for macrophages 
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Fxc. 1. IL-2 activity in culture supernatants derived from (a) 2-mo-old, and (b) 5-mo-old MRL-lpr 
(C)) and MRL-+/+ (Q) spleen cells. Each point represents he mean value of six individual mice. 
The dotted line shows the stimulatory effect of Con A (10 #g/ml) alone in the IL-2 assay. 
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determined by probit analysis as described by Gillis et al. (12). 
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Fro. 3. Effect of MRL-lpr spleen cells on IL-2 production by MRL-+/+ spleen cells. IL-2 activity 
was measured in supernatants derived from cocultures (&) of MRL-+/+ spleen cells (5 X 106/ml) 
and MRL-lpr spleen cells (5 × 106/ml). Control cultures, consisted of either MRL-+/+ (0) or 
MRL-lpr (O) cells alone at a concentration f5 × 106/ml. 
can be replaced in vitro by either phorbol myristic acetate (PMA) or the macrophage 
product,  IL-1 (26). To determine whether IL-2 deficiency in MRL-lpr mice reflects a 
macrophage defect rather than a pr imary T cell defect, we supplemented our cultures 
with these macrophage-replacing factors. Neither PMA nor IL-1 st imulated IL-2 
production by Con A-act ivated MRL-lpr spleen cells, a lthough they did enhance IL- 
2 production by control MRL-+/+ spleen cells (Fig. 4). Peak IL-2 product ion by 
MRL-+/+ spleen cells was associated with 10 ng /ml  PMA or a 1:10 di lut ion of our 
IL-1 preparat ion.  MRL-lpr spleen cells failed to produce IL-2 at PMA concentrations 
ranging from 5 to 20 ng /ml  and IL-1 dilutions ranging from 1:9 to 1:32. Neither 
PMA nor IL-1 st imulated IL-2 production in the absence of Con A, nor did PMA or 
IL-1 cause significant hymidine incorporation in the IL-2 assay (data not shown). 
Pathologic Features and IL-2 Production i  B6-lpr Mice. The characteristics of B6-1pr 
mice are summarized in Table I. B6-lpr mice had the typical features of disease seen 
in MRL-lpr mice: lymph nodes were increased in size 10-20-fold by 4 mo of age; 
antinuclear antibodies were present at 6 mo of age; and the median survival was 
shortened to 284 d, as compared with 795 d in control B6-+/+ mice. B6-lpr mice 
developed a defect in IL-2 activity early in life that became progressively more severe 
with age. Although spleen cells from 2-too-old B6-lpr mice produced IL-2 normal ly in 
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Fro. 4. Effect of 1:10 dilution of IL-1 preparation (©) or 10 ng/ml PMA (&) on Con A-induced 
IL-2 production by (a) MRL-lpr and (b) MRL-+/+ spleen cells. These concentrations of IL-1 and 
PMA resulted in maximum IL-2 production by MRL-+/+ spleen cells. The closed circles (0) 
represent Con A-induced IL-2 production in cultures not supplemented with IL-1 or PMA. 
TABLE I 
Characteristics of C57BL/ 6J-lpr/lpr mice 
Antinuclear 
Genotype Axillary lymph node antibodies at 6 Survival at 
size at 4 mo mo (number 10 mo:[: 
positive/total) * 
mg/g body wt +SEM % 
C57BL/6J-lpr/lpr 2.99 ± 0.67 6/6§ 37§ 
C57BL/6J-+/+ 0.18 + 0.01 0/8 96 
* Sera (1:10 dilution) tested by indirect immunofluorescence using rat liver 
sections as substrate (1). 
:[: Percent survival among 27 C57BL/6J-lpr/lpr mice and 24 C57BL/6J-+/+ 
mice. 
§ P <0.005 compared with C57BL/6J-+/+ mice (X 2 analysis of 2 X 2 contin- 
gency table). 
response to Con A, spleen cells from 3-mo-old mice showed a marked reduction in IL- 
2 activity (Fig. 5). There was virtual ly no IL-2 activity at 6 mo of age. 
Spleen Cell Response to IL-2. Con A-st imulated spleen cells from MRL- lpr  and B6- 
lpr mice prol i ferated significantly less in response to standard IL-2 preparat ions than 
did spleen cells from age-matched controls (Table II). Like the defect in IL-2 
production, the defect in IL-2 response was present in 2-mo-old MRL-lpr mice (P 
<0.05; t test for comparison of two independent means) and rose dramat ica l ly  by 5 
mo of age (P <10-5). 
Absorption of lL-2 Activity by Activated T Cells. The failure of MRL-lpr spleen cells to 
respond normal ly  to IL-2 suggested that they might be unable to b ind the lymphokine. 
To investigate this possibility, we incubated a standard IL-2 preparat ion with Con A- 
st imulated lymphocytes from either 5-mo-old MRL-lpr or MRL-+/+ mice. After 2 h 
of incubation with act ivated MRL-+/+ spleen cells (5 × 10r/ml), all of the IL-2 
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Fxo. 5. IL-2 activity in culture supernatants derived from 3-mo-old B6-lpr (O) and B6-+/+ (S) 
mice. Each point represents the mean value of IL-2 activity in four individual mice. 
TABLe II 
Spleen Cell Response toIL-2 
Number Thymidine incorpo- 
Spleen cell source of mice IL-2 source ration 
tested 
cpm 
MRL-lpr (2-mo-old) 7 Murine* 25,075 ± 6,152¢ 
MRL-+/+ (2-mo-old) 7 Murine 45,454 ± 6,091 
MRL-lpr (5-mo-old) 6 Murine 3,452 ± 1,660 
MRL-+/+ (5-mo-old) 6 Murine 43,392 ::1:4,417 
MRL-lpr (5-mo-old) 4§ Human H 1,010 
MRL-+/+ (5-mo-old) 4 Human 17,773 
B6-lpr (6-mo-old) 4 Human 2,590 ± 1,245 
B6-+/+ (6-mo-old) 4 Human 24,595 ± 6,210 
* Culture supernatant from Con A-stimulated MRL-+/+ cells. 
Mean ± SE. 
§ Pooled specimen. 
U Partially purified human IL-2. 
activity had been removed from the supernatant (Fig. 6). In contrast, incubation with 
MRL-lpr cells removed very little, if any, IL-2. 
Discussion 
Culture supernatants derived from Con A-activated MRL-lpr but not MRL--I-/+ 
spleen cells were deficient in IL-2 activity. In addition, MRL-lpr spleen cells responded 
poorly to IL-2. These defects were present early in life and became nearly absolute by 
5 mo of age. These findings suggest hat deficient IL-2 activity may contribute to 
impaired immunoregulation a d to the development of autoimmune disease. 
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FIG. 6. Activity of a standard IL-2 preparation before (&) and after absorption with Con A- 
stimulated MRL-Ipr (O) or MRL-+/+ (0) spleen cells. Absorptions were performed at37°C for 2 
h using 5 × 107 cells/ml. 
Because MRL-lpr and MRL-+/+ mice are congenic strains, we suspected that the 
lpr gene might code for a product that directly or indirectly caused deficient IL-2 
activity and impaired immunoregulation. This hypothesis was supported by our 
finding that C57BL/6J mice bearing the lpr gene also developed early IL-2 deficiency 
and subsequently a lupus-like illness. Thus, in two mouse strains, the lpr gene is 
associated with both IL-2 deficiency and autoimmune disease. 
We considered several mechanisms through which IL-2 deficiency might arise. 
Because production of IL-2 is macrophage dependent (26), a macrophage defect could 
result in decreased IL-2 production. Our observation that neither IL-1 nor PMA 
restored IL-2 production in MRL-lpr mice suggests that IL-2 deficiency is not due 
solely to a macrophage defect. In humans, Con A induces suppressor cells that 
suppress IL-2 production (27). We found no such suppressor cells in MRL-lpr mice, 
nor did MRL-lpr mice produce a soluble inhibitor of IL-2 activity. 
A structural abnormality might produce an IL-2 molecule lacking biological 
activity. However, this would not easily explain the increasing severity of IL-2 
deficiency with age. Alternatively, spleen cells capable of producing IL-2 may be 
diminished in frequency due to proliferation of other lymphocyte subpopulations. We 
doubt that an alteration in cell ratios is solely responsible for the IL-2 deficiency 
because this defect is present in young MRL-lpr mice in whom lymphoproliferation 
is mild. Furthermore, the proliferating cells in MRL-lpr mice are Lyt-1+23 - (3), as are 
the cells that normally produce IL-2 (28). 
Two signals are necessary for normal lymphocytes to proliferate in response to IL- 
2 (22, 29). First, they must be stimulated by mitogen or antigen because receptors for 
IL-2 are expressed on activated T cells but not on resting T cells. Second, they must 
be stimulated by IL-2. We have shown that Con A-stimulated MRL-+/+ spleen cells 
can absorb IL-2, whereas Con A-stimulated MRL-lpr spleen cells cannot. These 
findings imply that the poor response of MRL-lpr spleen cells in the IL-2 assay reflects 
an actual or functional deficiency of surface receptors for IL-2. The relationship 
between the defect in production of IL-2 and the defect in generation of IL-2 receptors 
is a problem for further study. However, it does not appear that these defects imply 
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reflect a generalized failure of Con A-stimulated responses because certain Con A- 
induced functions, such as cellular suppression of immunoglobulin synthesis (5), are 
normal even in old MRL-lpr mice. 
The relationship between IL-2 deficiency and autoimmunity is intriguing. Normal 
immunoregulation depends upon a complex set of cellular interactions (30) in which 
IL-2 appears to play an important role (14-18). IL-2 stimulates thymocyte prolifera- 
tion (14, 15), provides helper activity for antibody production (14-16), and facilitates 
the induction of cytotoxic T cells (14-18). Diminished IL-2 production might alter 
vital immune functions and thereby contribute to autoimmunity. Indeed, the de- 
pressed SMLR, which is considered to be a model for abnormal cellular interaction 
in autoimmune mice (10, 11), may be due to the deficiency of IL-2. There is a 
temporal correlation between the disappearance of IL-2 activity and the loss of 
syngeneic reactivity in MRL-lpr mice. Both occur early in life, before the onset of 
overt clinical disease. The defective cell in the SMLR bears the Lyt-1+23 - phenotype 
characteristic of IL-2-producing cells (11, 28). It has recently been shown that IL-2 is 
produced in the course of a normal SMLR (13). Its absence could contribute to the 
abnormal SMLR of MRL-lpr mice. 
The coexistence of T cell proliferation and reduced IL-2 activity in MRL-lpr mice 
may appear paradoxical. However, it is possible that controlled proliferation of Lyt- 
I+23 - T cells requires IL-2-dependent T cell differentiation. Uncontrolled prolifera- 
tion of Lyt-l÷23 - T cells might then arise as a consequence of IL-2 deficiency. 
Alternatively, the stimulus for lymphoproliferation i  MRL-lpr mice may be IL-2 
independent. 
The observation that IL-2 deficiency precedes the onset of overt autoimmune 
disease in two strains bearing the lpr gene (MRL, C57BL/6J) raises the possibility 
that the lpr mutation is causally related to murine lupus through defective T cell 
regulation arising as a consequence of the IL-2 abnormality. 
Summary  
Spleen cells from MRL-lpr and B6-lpr mice have a marked defect in the ability to 
produce interleukin 2 (IL-2) in response to concanavalin A stimulation. This defect 
precedes the onset of clinical illness, increases with age, and eventually becomes 
virtually absolute. It is not due to cellular suppression of IL-2 production, nor does it 
reflect the presence of a soluble inhibitor of IL-2 activity. Failure to restore IL-2 
production with macrophage-replacing factors, such as interleukin 1 and phorbol 
myristic acetate, suggests that IL-2 deficiency reflects a primary T cell defect rather 
than a macrophage defect. MRL-lpr and B6-lpr spleen cells also have an age- 
dependent reduction in IL-2 response that apparently results from a deficiency of cell 
surface receptors for IL-2. Congenic MRL-+/+ and B6-+/+ mice, which lack the lpr 
gene responsible for accelerated autoimmunity and lymphoproliferation, have normal 
IL-2 activity. These findings suggest hat a defect in IL-2 activity may contribute to 
impaired immunoregulation i  mice bearing the lpr gene. The absence of such a 
defect in MRL-+/+ and B6-+/+ mice further suggests that a single autosomal 
recessive gene is responsible for the IL-2 deficiency. 
We thank Dr. Robert Mishell for his advice and assistance in these studies. We gratefully 
acknowledge the technical contribution of Chris Kerger and Kathleen Roskos, and thank Sally 
Walsh for help in preparation of the manuscript. 
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